Daiichi's Benicar Pact Brings Payout Over Drugs to $339 Million
- Drugmaker agreed to pay $300 million to settle Benicar suits
- Company already paid $39 million in whistle-blower case
This article is for subscribers only.
Daiichi Sankyo Inc.’s settlement of thousands of lawsuits blaming the company’s blood-pressure drugs for causing intestinal damage brings to $339 million the amount the drugmaker has paid for its handling of the medicines.
Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its Benicar, Benicar HCT, Azor and Tribenzor blood-pressure treatments. The accord comes more than two years after the Chuo-Ku, Japan-based company paid $39 million to resolve the U.S. government’s allegations that it paid illegal kickbacks to doctors who prescribed the medicines.